Systemic treatment for metastatic castrate resistant prostate cancer: Does seqence matter?
Uro-Oncology
Related content
Uro-Oncology
Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with 177Lu-PSMA-I&T in Metastatic Castration-resistant Prostate Cancer
doi: 10.1016/j.eururo.2018.11.016.
Uro-Oncology
Response assessment using [68Ga]Ga-PSMA ligand PET in patients undergoing systemic therapy for metastatic castration-resistant prostate cancer
Prostate.
Grubmüller B, Rasul S, Baltzer P, Fajkovic H, D'Andrea D, Berndl F, Maj-Hes A, Grubmüller KH, Mitterhauser M, Wadsak W, Pfaff S, Shariat SF, Hacker M, Kramer G, Hartenbach M
doi: 10.1002/pros.23919.
Further Publications Urology
Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline ATM versus BRCA2 mutations
Prostate
Sokolova AO, Marshall CH, Lozano R, Gulati R, Ledet EM, De Sarkar N, Grivas P, Higano CS, Montgomery B, Nelson PS, Olmos D, Sokolov V, Schweizer MT, Yezefski TA, Yu EY, Paller CJ, Sartor O, Castro E, Antonarakis ES, Cheng HH
doi: 10.1002/pros.24236
COMMENTED
Uro-Oncology
Impact of Abiraterone Acetate plus Prednisone or Enzalutamide on Patient-reported Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer: Final 12-mo Analysis from the Observational AQUARiUS Study
★ 2
Recommended and commented by
Prof. Dr Richard Cathomas, Faculty Member
★ 3
Recommended by
Alexander Meisel, Faculty Member
Eur Urol.
Thiery-Vuillemin A, Hvid Poulsen M, Lagneau E, Ploussard G, Birtle A, Dourthe LM, Beal-Ardisson D, Pintus E, Trepiakas R, Lefresne F, Lukac M, Van Sanden S, Pissart G, Reid A, AQUARiUS Investigators.
doi: 10.1016/j.eururo.2019.09.019.
Uro-Oncology
Systemic treatments for high-risk localized prostate cancer
Nat Rev Urol.
Pignot G, Maillet D, Gross E, Barthelemy P, Beauval JB, Constans-Schlurmann F, Loriot Y, Ploussard G, Sargos P, Timsit MO, Vincendeau S, Pasticier G, Borchiellini D
doi: 10.1038/s41585-018-0017-x.
Uro-Oncology
Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Prostate Cancer Prostatic Dis
Wenzel M, Nocera L, Collà Ruvolo C, Würnschimmel C, Tian Z, Shariat SF, Saad F, Tilki D, Graefen M, Kluth LA, Briganti A, Mandel P, Montorsi F, Chun FKH, Karakiewicz PI
doi: 10.1038/s41391-021-00395-4
COMMENTED
Uro-Oncology
Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019
★ 2
Recommended and commented by
Prof. Dr Richard Cathomas, Faculty Member
doi: 10.1016/j.eururo.2020.01.012.
Uro-Oncology
Assessment of body composition in the advanced stage of castration-resistant prostate cancer: special focus on sarcopenia
Prostate Cancer Prostatic Dis.
Stangl-Kremser J, Suarez-Ibarrola R, Andrea D, Korn SM, Pones M, Kramer G, Marhold M, Krainer M, Enikeev DV, Glybochko PV, Tamandl D, Shariat SF, Baltzer P
doi: 10.1038/s41391-019-0186-6.
Uro-Oncology
Integrated analysis of pain, health-related quality of life, and analgesic use in patients with metastatic castration-resistant prostate cancer treated with Radium-223
Prostate Cancer Prostatic Dis
Badrising SK, Louhanepessy RD, van der Noort V, Kieffer J, Coenen JLLM, Hamberg P, Beeker A, Wagenaar N, Lam M, Celik F, Loosveld OJL, Oostdijk A, Zuetenhorst H, de Feijter JM, Dezentjé VO, Ras-van Spijk S, Vegt E, Haanen JB, van de Poll-Franse LV, Zwart W, Bergman AM
doi: 10.1038/s41391-021-00412-6